VML and Definitive Healthcare announce partnership to transform key opinion leader management
March 22, 2024 09:30 ET
|
Definitive Healthcare Corp.
FRAMINGHAM, Mass. and LONDON, March 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH) and VML Health announced a first-of-its-kind partnership that gives clients the ability to...
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024 07:00 ET
|
OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
January 17, 2023 16:30 ET
|
Aridis Pharmaceuticals, Inc.
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 ...
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
August 17, 2021 07:45 ET
|
Protagenic Therapeutics, Inc.
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
November 13, 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
June 01, 2020 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
March 24, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high...
Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease
January 30, 2018 11:14 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal...
Flat Fee Most Common Key Opinion Leader Compensation Method in Europe
August 04, 2011 10:50 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 4, 2011) - As scrutiny over key opinion leader (KOL) payments intensifies in Europe, life sciences companies set fee schedules and establish protocol...
Hard Limits on Thought Leader Compensation Employed Less Often by Pharma
July 21, 2011 12:06 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC and BOSTON, MA--(Marketwire - Jul 21, 2011) - As compliance and medical affairs teams prepare for the Sunshine Act, they are relying less on exact compensation limits for...